The efficacy & safety of various doses of fulranumab vs placebo for chronic LBP

Clin Ther. 2016 Jun;38(6):1435-50

Denosumab increases BMD and reduces bone turnover vs monthly oral bisphosphonate

Osteoporos Int. 2014 Jul;25(7):1953-61. doi: 10.1007/s00198-014-2692-7. Epub 2014 Mar 28.

WCO-IOF 2016: Greater BMD increase after 1 year of romosozumab vesus teripratide

Greater BMD increase with denosumab vs ZOL in patients switching from oral bisphosponates

J Clin Endocrinol Metab. 2016 Aug;101(8):3163-70

FREEDOM RCT follow-up: Denosumab does not delay fracture healing in osteoporosis patients

J Bone Joint Surg Am. 2012 Oct 24. doi: 10.2106/JBJS.K.00774

WCO-IOF 2016: Denosumab versus zoledronic acid following oral bisphosphonate therapy

Combination therapy improves site-specific BMD vs. teriparatide & denosumab monotherapies

J Clin Densitom. 2016 Jul-Sep;19(3):346-51

Denosumab is superior to alendronate for improving cortical bone porosity post-menopause

Bone. 2014 Feb;59:173-9. doi: 10.1016/j.bone.2013.11.016. Epub 2013 Nov 22.

Lower incidence of vertebral fracture with romosozumab vs placebo for osteoporosis

N Engl J Med. 2016 Oct 20;375(16):1532-1543

Denosumab and teriparatide significantly improves BMD in patients with osteoporosis

J Clin Endocrinol Metab. 2014 May;99(5):1694-700

Denosumab noninferior to zoledronic acid in the treatment of bone metastasis

J Clin Oncol. 2011 Mar 20;29(9):1125-32. doi: 10.1200/JCO.2010.31.3304. Epub 2011 Feb 22

COA/ICORS2019: No effect on fracture healing, improved ROM with ketotifen fumarate for reducing PTJC

Denosumab reduces secondary fragility fracture risk in osteoporotic women

Climacteric. 2015 Jun 1:1-23

Efficacy of combined teriparatide & denosumab vs. single-drug treatment for osteoporosis

J Clin Endocrinol Metab. 2016 May;101(5):2023-30

Combined teriparatide and denosumab treatment increased BMD in postmenopausal osteoporosis

Lancet. 2013 Jul 6;382(9886):50-6. doi: 10.1016/S0140-6736(13)60856-9. Epub 2013 May 15

Teriparatide increases BMD in patients with glucocorticoid-Induced osteoporosis

N Engl J Med. 2007 Nov 15;357(20):2028-39

Zoledronic acid reduces rates of new clinical fractures after hip fracture repair

N Engl J Med. 2007 Nov 1;357(18):1799-809. Epub 2007 Sep 17

Denosumab reduces risk of fractures in post-menopausal women

N Engl J Med. 2009 Aug 20;361(8):756-65. Epub 2009 Aug 11.

Early vs standard zoledronic acid treatments for prostate cancer metastatic to bone

J Clin Oncol. 2014 Apr 10;32(11):1143-50. doi: 10.1200/JCO.2013.51.6500.